Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev Jun. 1999, 20 (3): 345-357.
Article
CAS
Google Scholar
Chambers TJ: Regulation of the differentiation and function of osteoclasts. J Pathol. 2000, 192 (1): 4-13. 10.1002/1096-9896(2000)9999:9999<::AID-PATH645>3.0.CO;2-Q.
Article
CAS
PubMed
Google Scholar
Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000, 15 (1): 2-12. 10.1359/jbmr.2000.15.1.2.
Article
CAS
PubMed
Google Scholar
Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T: Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med. 1999, 190 (12): 1741-1754. 10.1084/jem.190.12.1741.
Article
CAS
PubMed
PubMed Central
Google Scholar
Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature. 2003, 423 (6937): 337-342. 10.1038/nature01658.
Article
CAS
PubMed
Google Scholar
Chung JY, Park YC, Ye H, Wu H: All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 2002, 115 (Pt 4): 679-688.
CAS
PubMed
Google Scholar
Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001, 104 (4): 487-501. 10.1016/S0092-8674(01)00237-9.
Article
CAS
PubMed
Google Scholar
Feng X: Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene. 2005, 350 (1): 1-13. 10.1016/j.gene.2005.01.014.
Article
CAS
PubMed
Google Scholar
Liu W, Xu D, Yang H, Xu H, Shi Z, Cao X, Takeshita S, Liu J, Teale M, Feng X: Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function. J Biol Chem. 2004, 279 (52): 54759-54769. 10.1074/jbc.M404687200.
Article
CAS
PubMed
Google Scholar
Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K: RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 1998, 253 (2): 395-400. 10.1006/bbrc.1998.9788.
Article
CAS
PubMed
Google Scholar
Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002, 416 (6882): 744-749. 10.1038/416744a.
Article
CAS
PubMed
Google Scholar
He S, Zhang D, Cheng F, Gong F, Guo Y: Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol Biol Rep. 2009, 36: 2153-2163. 10.1007/s11033-008-9429-7.
Article
CAS
PubMed
Google Scholar
Qin L, Zhang X, Zhang L, Feng Y, Weng GX, Li MZ, Kong QL, Qian CN, Zeng YX, Zeng MS, Liao DF, Song LB: Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 2008, 371 (3): 531-535. 10.1016/j.bbrc.2008.04.117.
Article
CAS
PubMed
Google Scholar
Eske K, Breitbach K, Köhler J, Wongprompitak P, Steinmetz I: Generation of murine bone marrow derived macrophages in a standardised serum-free cell culture system. J Immunol Methods. 2009, 342 (1–2): 13-19.
Article
CAS
PubMed
Google Scholar
Holt G, Murnaghan C, Reilly J, Meek RM: The biology of aseptic osteolysis. Clin Orthop Relat Res. 2007, 460: 240-252.
CAS
PubMed
Google Scholar
Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC: Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis. 2008, 25 (2): 119-129. 10.1007/s10585-007-9127-1.
Article
CAS
PubMed
Google Scholar
Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999, 96 (7): 3540-3545. 10.1073/pnas.96.7.3540.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shipman CM, Croucher PI: Osteoprotegerin is a soluble decoy receptor or tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003, 63 (5): 912-916.
CAS
PubMed
Google Scholar
Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P: RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther. 2009, 11 (6): R187-10.1186/ar2879.
Article
PubMed
PubMed Central
Google Scholar
Weiner LM: Fully human therapeutic monoclonal antibodies. J Immunotherapy. 2006, 29 (1): 1-9. 10.1097/01.cji.0000192105.24583.83.
Article
CAS
Google Scholar
Wada T, Nakashima T, Hiroshi N, Penninger JM: RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006, 2 (1): 17-25.
Article
Google Scholar
Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB: Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem. 1998, 273 (32): 20551-20555. 10.1074/jbc.273.32.20551.
Article
CAS
PubMed
Google Scholar
Yeon JT, Choi SW, Park KI, Choi MK, Kim JJ, Youn BS, Lee MS, Oh J: Glutaredoxin2 isoform b (Glrx2b) promotes RANKL-induced osteoclastogenesis through activation of the p38-MAPK signaling pathway. BMB Rep. 2012, 45 (3): 171-176. 10.5483/BMBRep.2012.45.3.171.
Article
CAS
PubMed
Google Scholar
Soriano P, Montgomery C, Geske R, Bradley A: Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991, 64 (4): 693-702. 10.1016/0092-8674(91)90499-O.
Article
CAS
PubMed
Google Scholar
Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998, 273 (23): 14363-14367. 10.1074/jbc.273.23.14363.
Article
CAS
PubMed
Google Scholar
Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T: Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest. 2004, 114 (4): 475-484.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, Kim HH: The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone. 2002, 30 (1): 71-77. 10.1016/S8756-3282(01)00657-3.
Article
CAS
PubMed
Google Scholar
Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M: Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem. 2000, 275 (40): 31155-31161.
Article
CAS
PubMed
Google Scholar
Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 2000, 408 (6812): 600-605. 10.1038/35046102.
Article
CAS
PubMed
Google Scholar
Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y, Ochi T: Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 1999, 42 (12): 2532-2542. 10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2.
Article
CAS
PubMed
Google Scholar
Tanaka S, Nakamura K, Takahasi N, Suda T: Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev. 2005, 208: 30-49. 10.1111/j.0105-2896.2005.00327.x.
Article
CAS
PubMed
Google Scholar
Amarzguioui M, Rossi JJ, Kim D: Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett. 2005, 579 (26): 5974-5981. 10.1016/j.febslet.2005.08.070.
Article
CAS
PubMed
Google Scholar
Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH: Delivery of RNA interference. Cell Cycle. 2006, 5 (18): 2103-2109. 10.4161/cc.5.18.3192.
Article
CAS
PubMed
Google Scholar